Flemington, New Jersey
United States
19
2022-08-18
12
2023-12-05
These are the the leading inventors for applications assigned to ARSTAT Inc.:
ARSTAT Inc. based in Flemington, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
#2 | 2020-10-22 ✅ Patent 11,351,132 granted on 2022-06-07Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
#3 | 2020-05-14 ✅ Patent 11,103,515 granted on 2021-08-31Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#4 | 2020-03-26 ✅ Patent 10,709,679 granted on 2020-07-14Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
#5 | 2019-09-19 ✅ Patent 10,537,582 granted on 2020-01-21Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#6 | 2019-07-04TREATMENT OF UTERINE FIBROIDS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL AGENT
#7 | 2019-06-27 ✅ Patent 10,532,037 granted on 2020-01-14Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
#8 | 2019-06-13 ✅ Patent 11,116,718 granted on 2021-09-14Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent
#9 | 2019-05-23TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY FEMININE SANITARY PRODUCTS MEDICATED WITH HEMOSTATIC AGENT
#10 | 2019-01-24 ✅ Patent 10,463,678 granted on 2019-11-05Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#11 | 2018-07-26 ✅ Patent 10,111,887 granted on 2018-10-30Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#12 | 2017-08-31 ✅ Patent 9,925,199 granted on 2018-03-27Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#13 | 2014-10-02 ✅ Patent 9,675,622 granted on 2017-06-13Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
#14 | 2014-02-06ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS
#15 | 2014-01-30TREATMENT OF MENSTRUAL PAIN AND EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUG
#16 | 2014-01-02TREATMENT OF UTERINE FIBROIDS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL
#17 | 2014-01-02 ✅ Patent 10,251,836 granted on 2019-04-09Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent
#18 | 2013-12-26TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY FEMININE SANITARY PRODUCTS MEDICATED WITH ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT
#19 | 2013-12-19TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF LOW DOSES OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT
Also check out ARSTAT, INC.'s (Flemington, United States) applicant profile with 12 patent applications submitted.
49158 ⎘